The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 318 participants.
Also called NCT01364220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 318 participants
- Sponsor
- Registry
-
NCT01364220
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Terminated
Technical summary
Registry record NCT01364220. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
- Acronym
- EUREKA
- Condition
- Stroke
- Intervention (Drug)
- Rosuvastatin
- Intervention (Other)
- Placebo tablet
- Lead sponsor
- Severance Hospital
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct01364220- Content hash
50a9b07615cb0215dba793db61dadec8865814bced952b3850eaf7b5088fa7bd